Influence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinoma

Cancer

Volumn 118, Issue 24, 2012, Pages 6243-6252

  Rose, Jeffrey S ^a   Serna, Derek S ^b   Martin, Ludmila Katherine ^a   Li, Xiaobai ^c   Weatherby, Lynn M ^a   Abdel Misih, Sherif ^c   Zhao, Weiqiang ^d   Bekaii Saab, Tanios ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b Reid Oncology Associates   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

KRAS; metastatic colorectal adenocarcinoma; mutation; prognosis

Indexed keywords

BEVACIZUMAB; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; COLORECTAL CARCINOMA; CONTROLLED STUDY; EXON; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; ONCOGENE K RAS; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; NEOPLASMS, MULTIPLE PRIMARY; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TERTIARY CARE CENTERS; YOUNG ADULT;

EID: 84870670197     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27666     Document Type: Article

References (27)

1. Vogelstein B, Fearon E, Hamilton S, et al. Genetic alterations during colorectal tumor development. N Engl J Med. 1988; 319: 525-532.
2. Linardou H, Briasoulis E, Dahabreh IJ, et al. All about KRAS for clinical oncology practice: gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer. Cancer Treat Rev. 2011; 37: 221-233.
3. McDermott U, Longley DB, Johnston PG,. Molecular and biochemical markers in colorectal cancer. Ann Oncol. 2002; 13 (suppl 4): 235-245.
4. Bos JL,. Ras oncogenes in human cancer: a review. Cancer Res. 1989; 49: 4882-4689.
5. Edkins S, O'Meara S, Parker A, et al. Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther. 2006; 5: 928-932.
6. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007; 357: 2040-2048.
7. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care in patients with chemotherapy-refractory colorectal cancer. J Clin Oncol. 2007; 25: 1658-1664.
8. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26: 1626-1634.
9. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. KRAS mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008; 359: 1757-1765.
10. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009; 27: 2091-2096.
11. Price TJ, Hardingham JE, Chee K, et al. Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer. J Clin Oncol. 2001; 29: 2675-2682.
12. Hecht JR, Mitchell E, Chidiak T, et al. A randomized phase IIIb trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2008; 27: 672-680.
13. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009; 360: 563-572.
14. Richman SD, Seymour MT, Chambers P, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol. 2009; 27: 5931-5937.
15. Maughan TS, Adams R, Smith CG, et al. Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy (CT) in first-line advanced colorectal cancer: mature results of the MRC COIN trial [abstract]. J Clin Oncol. 2010; 28 (15s). Abstract 3502.
16. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, and SAKK 60-00 trial. J Clin Oncol. 2010; 28: 466-474.
17. Van Cutsem E, Kohne CH, Lang I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011; 29: 2011-2019.
18. Moosmann N, von Weikersthal LF, Vehling-Kaiser U, et al. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104-a randomized trial of the German AIO CRC Study Group. J Clin Oncol. 2011; 29: 1050-1058.
19. Andreyev HJN, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the "RASCAL II" study. Br J Cancer. 2001; 85: 692-696.
20. Alberts SR, Thibodeau SN, Sargent DJ, et al. Influence of KRAS and BRAF mutational status and rash on disease-free survival in patients with resected stage III colon cancer receiving cetuximab: results from NCCTG N0147 [abstract]. J Clin Oncol. 2011; 29 (suppl). Abstract 3607.
21. Aust DE, Lutz MP, Mauer M, et al. Lessons from PETACC-2: no prognostic impact of KRAS-/BRAF-status in stage II colon cancer treated with adjuvant 5-FU monotherapy [abstract]. J Clin Oncol. 2010; 28 (15s). Abstract 3591.
22. Ogino S, Meyerhardt JA, Irahara N, et al. KRAS mutation in stage III colon cancer and clinical outcome following Intergroup Trial CALGB 89803. Clin Cancer Res. 2009; 15: 7322-7329.
23. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999; 230: 309-318.
24. De Roock W, Jonker DJ, Di Nicolantonio F, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 2010; 304: 1812-1820.
25. Peeters M, Douillard JY, Van Cutsem E, et al. Mutant (MT) KRAS codon 12 and 13 alleles in patients (pts) with metastatic colorectal cancer (mCRC): assessment as prognostic and predictive biomarkers of response to panitumumab (pmab) [abstract]. J Clin Oncol. 2012; 30 (suppl 4). Abstract 383.
26. Fransen K, Klintenas M, Osterstrom A, et al. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis. 2004; 25: 527-533.
27. Ogino S, Nosho K, Kirkner GJ, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2009; 58: 90-96.